 
                GLP-1 Drugs, Weight Loss & Midlife: What You Need to Know
Artikel konnten nicht hinzugefügt werden
Der Titel konnte nicht zum Warenkorb hinzugefügt werden.
Der Titel konnte nicht zum Merkzettel hinzugefügt werden.
„Von Wunschzettel entfernen“ fehlgeschlagen.
„Podcast folgen“ fehlgeschlagen
„Podcast nicht mehr folgen“ fehlgeschlagen
- 
    
        
 
	
Gesprochen von:
- 
    
        
 
	
Von:
Über diesen Titel
GLP-1 medications like Ozempic, Wegovy, and Mounjaro are everywhere right now—and for good reason. They promise significant weight loss, and yes, they often deliver. But what’s really going on behind the scenes?
In this episode of The Midlife Mud, Morgan and Chris explore how GLP-1 drugs work, why they’re making waves in the weight loss world, and what people most often overlook when considering them, especially in the context of midlife.
They cover:
- How GLP-1 medications affect blood sugar, appetite, and weight regulation
- Why midlife metabolism changes the game (hello, stress and hormone shifts)
- The pros: weight loss, lower cholesterol, improved insulin sensitivity
- The cons: muscle loss, side effects, weight regain after stopping
- What to consider before starting these medications
- Why a holistic, intentional health strategy still matters
- Plus: a story about bread that says a lot about how we’ve approached weight loss over the years 🥖
Whether you're GLP-1 curious, skeptical, or just trying to make sense of the midlife health landscape, you’ll walk away from this episode feeling more informed and better equipped to make decisions that actually fit you.
👉 Join our community for honest conversations, support, and resources at:
 www.themidlifemud.com/join
Talk to us!
 
            
         
    
                                     
    
                                                
                                            
                                        
                                    
                            
                            
                        
                    